hypertension and diabetic nephropathy. Findings from this study
also supported once-a-day oral dosing of PS433540 as the compound
successfully demonstrated its ability to block the angiotensin II-
induced blood pressure increase for 24 hours.
-- PS433540 demonstrated positive results in a multiple ascending dose
study. This safety and tolerability study was initially designed to
evaluate 14 days of daily dosing in healthy volunteers, at dose
levels of 50, 100, 250 and 500 mg of PS433540. As no safety or
tolerability issues were observed with any of these doses, the study
was expanded to include a 1,000 mg dose. As with previous lower
doses, there were no safety or tolerability issues observed with the
1,000 mg dose of PS433540.
-- Pharmacopeia announced that Bristol-Myers Squibb Company (BMS)
initiated a Phase 2 clinical trial with a p38 kinase inhibitor,
PS540446, that resulted from a collaborative research program between
the two companies. PS540446 is being evaluated for the oral treatment
of moderate to severe psoriasis.
-- Pharmacopeia announced that it earned a $1 million milestone payment
from Schering-Plough as the result of the initiation of a Phase 1
clinical trial in the United States for PS948115, a compound identified
from the collaboration between the two companies. The compound is
being evaluated as a potential treatment for respiratory disease.
Pharmacopeia is eligible to receive additional milestone payments for
PS540446 and PS948115 if the programs are advanced further in clinical
trials by BMS and Schering-Plough, respectively. The company will also
receive royalties on sales of any resulting therapeutic products
incorporating compounds derived from the progr
Copyright©2007 PR Newswire.
All rights reserved